Clinical Trials Browser

Completed × Ovarian Neoplasms × Imatinib Mesylate × Clear all

NCT00216112 2016-02-19

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT00039585 2015-04-30

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00928642 2014-10-21

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Phase 2 Completed

8 enrolled 8 charts

Neoplasms, Ovarian Neoplasms

NCT00510653 2013-08-23

Gleevec Study for Patients With Ovarian Cancer

Phase 2 Completed

73 enrolled 4 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00006357 2012-09-24

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Phase 1/2 Completed

GastrointestinalGynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous